Lilly submits baricitinib NDA, triggers Incyte milestone

Eli Lilly and Co. (NYSE:LLY) submitted an NDA to FDA for baricitinib ( LY3009104) to treat moderate to severe rheumatoid arthritis, triggering a $35 million milestone payment to Incyte Corp. (NASDAQ:INCY) from the pharma.

The partners share rights to baricitinib under a 2009 deal. Incyte exercised a co-development option in RA the following year (see BioCentury Extra, Dec. 21, 2009). ...